What is Zacks Research's Forecast for PBH Q3 Earnings?

Key Points

• Zacks Research has lowered its Q3 2026 earnings per share estimate for Prestige Consumer Healthcare to $1.21, down from the previous estimate of $1.23, reflecting a Strong Sell rating on the stock.
• Canaccord Genuity has reduced its price target for the company from $105 to $100, while Wall Street Zen downgraded the stock from a "buy" to a "hold" rating.
• Prestige Consumer Healthcare reported Q2 earnings of $0.95 per share, missing estimates by $0.06 with revenues of $249.53 million, down 6.6% year-over-year.

Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) - Research analysts at Zacks Research lowered their Q3 2026 earnings estimates for Prestige Consumer Healthcare in a research report issued to clients and investors on Tuesday, September 16th. Zacks Research analyst Team now anticipates that the company will post earnings per share of $1.21 for the quarter, down from their prior forecast of $1.23. Zacks Research has a "Strong Sell" rating on the stock. The consensus estimate for Prestige Consumer Healthcare's current full-year earnings is $4.50 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare's Q4 2026 earnings at $1.36 EPS, Q3 2027 earnings at $1.10 EPS and FY2027 earnings at $4.82 EPS.

Several other equities research analysts have also recently weighed in on the stock. Canaccord Genuity Group dropped their price target on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Wall Street Zen downgraded shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Three investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $93.33.

Prestige Consumer Healthcare Price Performance

Prestige Consumer Healthcare stock traded down $0.99 during midday trading on Wednesday, reaching $63.11. 1,033,476 shares of the stock were exchanged, compared to its average volume of 567,570. The company's fifty day moving average is $69.07 and its 200-day moving average is $78.44. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.99 and a current ratio of 4.38. The firm has a market cap of $3.11 billion, a PE ratio of 14.81, a PEG ratio of 1.99 and a beta of 0.46. Prestige Consumer Healthcare has a 52 week low of $61.93 and a 52 week high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.95 earnings per share for the quarter, missing analysts' consensus estimates of $1.01 by ($0.06). The firm had revenue of $249.53 million for the quarter, compared to the consensus estimate of $260.71 million. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.Prestige Consumer Healthcare's quarterly revenue was down 6.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.90 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS.

Institutional Trading of Prestige Consumer Healthcare

Several institutional investors have recently modified their holdings of PBH. GAMMA Investing LLC increased its position in Prestige Consumer Healthcare by 35.9% in the 1st quarter. GAMMA Investing LLC now owns 1,879 shares of the company's stock worth $162,000 after purchasing an additional 496 shares during the last quarter. KBC Group NV grew its holdings in Prestige Consumer Healthcare by 7.4% in the 1st quarter. KBC Group NV now owns 2,199 shares of the company's stock valued at $189,000 after buying an additional 151 shares during the last quarter. QRG Capital Management Inc. lifted its position in shares of Prestige Consumer Healthcare by 8.6% in the 1st quarter. QRG Capital Management Inc. now owns 5,971 shares of the company's stock worth $513,000 after acquiring an additional 475 shares during the period. Intech Investment Management LLC raised its stake in Prestige Consumer Healthcare by 18.9% during the first quarter. Intech Investment Management LLC now owns 27,307 shares of the company's stock worth $2,348,000 after acquiring an additional 4,343 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its position in Prestige Consumer Healthcare by 14.1% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 8,315 shares of the company's stock valued at $649,000 after purchasing an additional 1,030 shares during the last quarter. Institutional investors and hedge funds own 99.95% of the company's stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.